ClinicalTrials.gg
CompletedNCT02713178Updated Dec 1, 2020Results posted

Efficacy, Safety, and Pharmacokinetics of Femoral Nerve Block With EXPAREL in Total Knee Arthroplasty

A Phase 3 interventional study of bupivacaine liposome injectable suspension and Placebo in Pain, sponsored by Pacira Pharmaceuticals, Inc. Completed at 17 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-01.

Sponsored by Pacira Pharmaceuticals, Inc · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
232
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing Liposomal Bupivacaine in Pain — 5 open to participants now, 5 under way, 2 of them phase 3. Liposomal Bupivacaine · Pain.

Enrollment
2nd of 36
232 · median 60
Started
2016
with 2 others
Phase 3
6 of 36
1 open now
Registered
20th of 36
by date
Lead sponsor
7 of 36
Pacira Pharmaceuticals, Inc

Among the 36 studies testing Liposomal Bupivacaine in Pain, this one is the 2nd largest by enrollment, is one of 3 that started in 2016, is one of 6 in phase 3, and was the 20th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

5 of the 36 studies testing Liposomal Bupivacaine in Pain are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

About Liposomal Bupivacaine

Liposomal Bupivacaine: first FDA approval 2011 (EXPAREL), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing Liposomal Bupivacaine in Pain, or all of them as a file.
02

Study summary

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study in 232 adult subjects undergoing primary unilateral TKA under general or spinal anesthesia.

Read the detailed description

On Day 0, eligible subjects will be randomized in a 1:1:1 ratio to receive a single dose of either EXPAREL 133 mg in 10 mL expanded in volume with 10 mL of normal saline for a total volume of 20 mL (Group 1); EXPAREL 266 mg in 20 mL (Group 2); or placebo 20 mL (Group 3). Study drug (EXPAREL or placebo) will be administered in a blinded manner via an ultrasound guided single-dose femoral nerve block at least 1 hour prior to surgery. Prior to placement of the prosthesis, 8 mL of bupivacaine hydrochloride (HCl) (0.5%) diluted with 8 mL of normal saline will be administered by the surgeon as a periarticular infiltration to the posterior capsule (8 mL medially and 8 mL laterally).

Postsurgical assessments will include pain intensity scores using a 10-cm visual analog scale (VAS); total postsurgical opioid consumption; overall benefit of analgesia score (OBAS) questionnaire; subject satisfaction with overall analgesia using a 5-point Likert scale; neurological assessment; sensory function assessment; motor function assessment; the study physical therapy assessments (ie, timed walk, timed up and go, and stair climbing tests); discharge readiness; unscheduled phone calls or office visits related to pain; 12-lead ECGs; vital sign measurements; and clinical laboratory tests. Adverse events will be recorded from the time the informed consent form (ICF) is signed through postsurgical Day 29.

Follow-up visits will be scheduled for all subjects on postsurgical Days 6 and 10. A follow-up phone call will be made on postsurgical Day 29.

Pharmacokinetic (PK) parameters will be estimated from plasma bupivacaine measurements using non-compartmental analysis based on the sampling schedule of baseline (prior to the nerve block) through postsurgical Day 10.

03

Conditions studied

  • Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, at least 18 years of age at screening.
  2. Scheduled to undergo primary unilateral TKA under general or spinal anesthesia.
  3. (ASA) physical status 1, 2, or 3.
  4. Female subject must be surgically sterile; or at least 2 years ; or have a monogamous partner who is surgically sterile; or practicing double-barrier ; or practicing abstinence (must agree to use double-barrier contraception in the event of sexual activity); or using an insertable, injectable, transdermal, or combination oral contraceptive approved by the FDA for greater than 2 months prior to screening and commit to the use of an acceptable form of birth control for the duration of the study and for 30 days after completion of the study.
  5. Able to demonstrate sensory function by exhibiting sensitivity to cold, pinprick, and light touch.
  6. Able to provide , adhere to the study visit schedule, and complete all study assessments.

Exclusion criteria

Exclusion Criteria:

  1. Currently pregnant, nursing, or planning to become pregnant during the study or within 1 month after study drug administration.
  2. Planned concurrent surgical procedure (e.g., bilateral TKA).
  3. Concurrent painful physical condition that may require analgesic treatment (such as an NSAID or opioid) in the postsurgical period for pain that is not strictly related to the knee surgery and which may confound the postsurgical assessments (e.g., significant pain from other joints including the non-index knee joint, chronic neuropathic pain, concurrent or prior contralateral TKA, concurrent foot surgery).
  4. Previous open knee surgery on the knee being considered for TKA. Prior arthroscopy is permitted.
  5. History of or idiosyncratic reaction to amide-type local anesthetics.
  6. to any one of the following: bupivacaine, oxycodone, morphine, or hydromorphone.
  7. Use of any of the following medications within the times specified before surgery: long-acting opioid medication or NSAIDs (except for low-dose aspirin used for cardioprotection) within 3 days, or any opioid medication within 24 hours.
  8. Initiation of treatment with any of the following medications within 1 month of study drug administration or if the medication(s) are being given to control pain: selective serotonin reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors (SNRIs), gabapentin, pregabalin (Lyrica®), or duloxetine (Cymbalta®). If a subject is taking one of these medications for a reason other than pain control, he or she must be on a stable dose for at least 1 month prior to study drug administration.
  9. Current use of systemic glucocorticosteroids within 1 month of enrollment in this study.
  10. Use of dexmedetomidine HCl (Precedex®) within 3 days of study drug administration.
  11. History of impaired kidney function, poorly controlled chronic respiratory disease, rheumatoid arthritis, coagulopathy, or loss of sensation in extremities.
  12. Impaired kidney function (e.g., serum creatinine level >2 mg/dL [176.8 µmol/L] or blood urea nitrogen level >50 mg/dL [17.9 mmol/L]) or impaired liver function (e.g., serum [AST] level >3 times the [ULN] or serum alanine aminotransferase [ALT] level >3 times the ULN.)
  13. Uncontrolled anxiety, psychiatric, or neurological disorder that might interfere with study assessments.
  14. Any chronic neuromuscular deficit effecting the peripheral nerves or muscles of the surgical extremity.
  15. Any chronic condition or disease that would compromise neurological or vascular assessments.
  16. in the last 2 years, with the exception of non- basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix.
  17. Suspected or known history of drug or alcohol abuse within the previous year.
  18. Body weight \<50 kg (110 pounds) or a >44 kg/m2.
  19. Previous participation in an EXPAREL study.
  20. Administration of an drug within 30 days or 5 elimination half-lives of such investigational drug, whichever is longer, prior to study drug administration, or planned administration of another investigational product or procedure during the subject's participation in this study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
232 participants (actual)

Study arms

  • Active comparator
    EXPAREL 133 mg

    Single dose of 133 mg (10 mL) EXPAREL (bupivacaine liposome injectable suspension) expanded in volume with 10 mL of normal saline for a total volume of 20 mL.

    Drug: bupivacaine liposome injectable suspension

  • Active comparator
    EXPAREL 266 mg

    Single dose of 266 mg (20 mL) EXPAREL (bupivacaine liposome injectable suspension).

    Drug: bupivacaine liposome injectable suspension

  • Placebo comparator
    Placebo

    Normal saline (20 mL).

    Drug: Placebo

Interventions

  • bupivacaine liposome injectable suspension 133 mg expanded with normal saline to 20 mL or 266 mg in 20 mL

    Also known as: EXPAREL

  • DrugPlacebo

    Normal saline.

    Also known as: Normal saline

06

What researchers measure

Primary outcomes

  1. Area Under the Curve (AUC) of Visual Analog Scale (VAS) Pain Intensity Scores Through 72 Hours

    AUC of VAS pain intensity scores through 72 hours. Visual Analog Scale (VAS) is a pain scale. The VAS was presented as a straight 10 cm line, where 0 cm is no pain and 10 cm is the worst pain possible. Patients were asked, "How much pain are you experiencing right now? Please place a vertical mark on the line below to indicate the level of pain you are experiencing right now."

    Time frame: 0-72 hours

Secondary outcomes

  1. Total Postsurgical Opioid Consumption Through 72 Hours

    Total postsurgical opioid consumption (converted to IV morphine equivalents) through 72 hours

    Time frame: 0-72 hours

  2. Percentage of Opioid-free Participants Through 72 Hours

    Percentage of participants who did not receive opioid medication through 72 hours

    Time frame: 0-72 hours

  3. Time to First Opioid Rescue Through 72 Hours

    Time to first opioid rescue medication consumed through 72 hours. The "time to rescue" is estimated for each quartile from the Kaplan-Meier analysis, in which first quartile represents the time it took for the first 25% of the population to receive rescue medication, median quartile represents the time it took 50% of the population to receive rescue medication, and third quartile represents the time it took 75% of the population to receive rescue medication.

    Time frame: 0-72 hours

07

Results

Posted Dec 1, 2020

Participant flow

Participants were recruited between June 3, 2016 and June 30, 2017 at 13 sites in the US and Europe

Participant flow — Overall Study
MilestoneEXPAREL 133 mgEXPAREL 266 mgPlacebo
Started767779
Completed757374
Not completed145

Outcome measures

PrimaryArea Under the Curve (AUC) of Visual Analog Scale (VAS) Pain Intensity Scores Through 72 Hours

AUC of VAS pain intensity scores through 72 hours. Visual Analog Scale (VAS) is a pain scale. The VAS was presented as a straight 10 cm line, where 0 cm is no pain and 10 cm is the worst pain possible. Patients were asked, "How much pain are you experiencing right now? Please place a vertical mark on the line below to indicate the level of pain you are experiencing right now."

Time frame:
0-72 hours
Reported as:
Least squares mean · cm*hr
Area Under the Curve (AUC) of Visual Analog Scale (VAS) Pain Intensity Scores Through 72 Hours
cm*hrEXPAREL 133 mgEXPAREL 266 mgPlacebo
Area Under the Curve (AUC) of Visual Analog Scale (VAS) Pain Intensity Scores Through 72 Hours259.545 ± 19.011250.998 ± 18.849279.794 ± 18.493
Statistical analysis
  • EXPAREL 133 mg vs Placebo · ANOVA · p = 0.4463 · Lsmd: -20.249 · 95% CI -72.361 to 31.864
  • EXPAREL 266 mg vs Placebo · ANOVA · p = 0.2749 · Lsmd: -28.796 · 95% CI -80.483 to 22.892
SecondaryTotal Postsurgical Opioid Consumption Through 72 Hours

Total postsurgical opioid consumption (converted to IV morphine equivalents) through 72 hours

Time frame:
0-72 hours
Reported as:
Least squares mean · mg
Total Postsurgical Opioid Consumption Through 72 Hours
mgEXPAREL 133 mgEXPAREL 266 mgPlacebo
Total Postsurgical Opioid Consumption Through 72 Hours69.466 ± 4.40374.393 ± 4.66981.469 ± 5.006
Statistical analysis
  • EXPAREL 133 mg vs Placebo · ANOVA · p = 0.0716 · Lsm treatment ratio: 0.853 · 95% CI 0.717 to 1.014
  • EXPAREL 266 mg vs Placebo · ANOVA · p = 0.3004 · Lsm treatment ratio: 0.913 · 95% CI 0.769 to 1.084
SecondaryPercentage of Opioid-free Participants Through 72 Hours

Percentage of participants who did not receive opioid medication through 72 hours

Time frame:
0-72 hours
Reported as:
Count of participants · Participants
Percentage of Opioid-free Participants Through 72 Hours
ParticipantsEXPAREL 133 mgEXPAREL 266 mgPlacebo
Percentage of Opioid-free Participants Through 72 Hours000
SecondaryTime to First Opioid Rescue Through 72 Hours

Time to first opioid rescue medication consumed through 72 hours. The "time to rescue" is estimated for each quartile from the Kaplan-Meier analysis, in which first quartile represents the time it took for the first 25% of the population to receive rescue medication, median quartile represents the time it took 50% of the population to receive rescue medication, and third quartile represents the time it took 75% of the population to receive rescue medication.

Time frame:
0-72 hours
Reported as:
Number · h
Time to First Opioid Rescue Through 72 Hours
hEXPAREL 133 mgEXPAREL 266 mgPlacebo
First quartile1.80 (0.87 to 2.22)1.53 (0.75 to 2.13)1.08 (0.65 to 1.65)
Second quartile3.03 (2.38 to 3.85)2.87 (2.25 to 3.47)2.40 (1.68 to 2.90)
Third quartile5.07 (4.15 to 7.25)5.78 (3.98 to 8.12)3.72 (3.15 to 5.07)
Statistical analysis
  • EXPAREL 133 mg vs Placebo · Log Rank · p = 0.1896
  • EXPAREL 266 mg vs Placebo · Log Rank · p = 0.2549

Adverse events

Collected over From screening to day 29 postsurgery. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
EXPAREL 133 mg0/75 (0%)5/75 (6.7%)73/75 (97.3%)
EXPAREL 266 mg0/76 (0%)8/76 (10.5%)74/76 (97.4%)
Placebo0/79 (0%)6/79 (7.6%)76/79 (96.2%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventEXPAREL 133 mgEXPAREL 266 mgPlacebo
Postprocedural hematomaInjury, poisoning and procedural complications3/751/760/79
Motor dysfunctionNervous system disorders0/752/760/79
Atrial fibrillationCardiac disorders1/751/761/79
Postprocedural swellingInjury, poisoning and procedural complications1/750/760/79
CellulitisInfections and infestations1/750/760/79
Sinus bradycardiaCardiac disorders0/751/760/79
Transient ischemic attackNervous system disorders0/751/760/79
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/751/760/79
Anaphylactic shockImmune system disorders0/751/760/79
BradycardiaCardiac disorders0/750/761/79
Most frequent other events
Showing 10 of 26
Most frequent other events
EventEXPAREL 133 mgEXPAREL 266 mgPlacebo
Motor dysfunctionNervous system disorders34/7535/7634/79
NauseaGastrointestinal disorders27/7534/7624/79
PyrexiaGeneral disorders23/7518/7622/79
ConstipationGastrointestinal disorders12/7516/7615/79
VomitingGastrointestinal disorders4/7510/769/79
Urinary retentionRenal and urinary disorders3/7510/768/79
PruritusSkin and subcutaneous tissue disorders4/758/7610/79
HypotensionVascular disorders8/754/765/79
Hepatic enzyme increasedInvestigations7/751/763/79
DizzinessNervous system disorders3/757/765/79

Baseline characteristics

Safety population included all participants who received study drug, with analysis by actual treatment received.

Age, Continuous
Age, Continuous(years)EXPAREL 133 mgEXPAREL 266 mgPlaceboTotal
Mean64.6 ± 6.9466.0 ± 9.0165.4 ± 8.6965.3 ± 8.26
Sex: Female, Male
Sex: Female, Male(Participants)EXPAREL 133 mgEXPAREL 266 mgPlaceboTotal
Female364353132
Male39332698
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)EXPAREL 133 mgEXPAREL 266 mgPlaceboTotal
Hispanic or Latino2226
Not Hispanic or Latino737475222
Unknown or Not Reported0022
Race (NIH/OMB)
Race (NIH/OMB)(Participants)EXPAREL 133 mgEXPAREL 266 mgPlaceboTotal
American Indian or Alaska Native0000
Asian0101
Native Hawaiian or Other Pacific Islander0000
Black or African American851225
White666967202
More than one race0000
Unknown or Not Reported1102
Region of Enrollment
Region of Enrollment(participants)EXPAREL 133 mgEXPAREL 266 mgPlaceboTotal
Belgium363736109
United States383840116
Denmark1135
Visual analog scale pain score
Visual analog scale pain score(cm)EXPAREL 133 mgEXPAREL 266 mgPlaceboTotal
Mean2.12 ± 2.6562.08 ± 2.5461.80 ± 2.1951.99 ± 2.458
American Society of Anesthesiologists classification
American Society of Anesthesiologists classification(Participants)EXPAREL 133 mgEXPAREL 266 mgPlaceboTotal
Score: 11191030
Score: 2414146128
Score: 323262372
Score: Greater than or equal to 40000
08

Study locations

17 sites
  • Horizon Research Group, Inc
    Mobile, Alabama 36608, United States
  • Denver Metro Orthopedics
    Englewood, Colorado 80113, United States
  • Jackson Memorial Hospital/University of Miami
    Miami, Florida 33136, United States
  • Pensacola Research Associates
    Pensacola, Florida 32504, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02215, United States
  • Montefiore Medical Center
    Bronx, New York 10467, United States
  • Fairview Hospital
    Cleveland, Ohio, United States
  • Indiana Regional Medical Center
    Indiana, Pennsylvania 15701, United States
  • Thomas Jefferson University Hospital
    Philadelphia, Pennsylvania 19107, United States
  • Chan Soon-Shiong Medical Center
    Windber, Pennsylvania 15963, United States
  • Hermann Drive Surgical Hospital
    Houston, Texas 77004, United States
  • Westside Surgical Hospital
    Houston, Texas 77027, United States
  • Southampton Orthopaedics Sports Medicine
    Franklin, Virginia, United States
  • Ziekenhuis Oost-Limburg
    Genk, Belgium
  • Aarhus University Hospital
    Aarhus C, Denmark
  • Regionshospital Silkeborg
    Silkeborg, Denmark
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2016, a primary completion of Jun 2017 and a completion of Jun 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2020, 3 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2016
First posted
Mar 18, 2016
Start
Jun 3, 2016
Primary completionActual
Jun 30, 2017
CompletionActual
Jun 30, 2017
Results first posted
Dec 1, 2020
Last update
Dec 1, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 1, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02713178
Responsible party
Sponsor
First posted
Mar 18, 2016
Start date
Jun 3, 2016
Primary completion
Jun 30, 2017
Completion
Jun 30, 2017
Results posted
Dec 1, 2020
Last update
Dec 1, 2020

Study contacts

James B Jones, MD, PharmD
study director · Pacira Pharmaceuticals, Inc

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liposomal Bupivacaine

Start the discussion